RxDoctor Payments Data

Kenneth Hawk, NP

Family · Oakland, MDNPI 1427047240

Payments from drug & device makers

$669in general payments, 2019–2025

Across 37 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$158
  • Exact Sciences$157
  • Novo Nordisk$64
  • AbbVie$64
  • Pfizer$57
  • Insulet Corporation$48
  • plus $120 from 5 others

What the payments were for

  • Food & beverage$64697%
  • Education$233%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$669 in reported general payments places this provider in the 60th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$130,941
Medicare patients
490
Services billed
2,702

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide94$131,000
EliquisApixaban103$100,035
MounjaroTirzepatide63$86,475
JardianceEmpagliflozin94$86,036
JanuviaSitagliptin Phosphate63$72,374
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$52,228
XareltoRivaroxaban60$46,479
FarxigaDapagliflozin Propanediol38$44,367
XifaxanRifaximin12$44,336
TrulicityDulaglutide27$25,232
LinzessLinaclotide21$22,463
Tresiba Flextouch U-200Insulin Degludec15$17,188
RybelsusSemaglutide11$14,515
Tresiba Flextouch U-100Insulin Degludec23$11,991
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$8,196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$64$145,515105 claims
PfizerEliquis$57$100,035103 claims
GSKTrelegy Ellipta$158$52,22849 claims
AstraZenecaFarxiga, Symbicort$14$50,31853 claims
AbbVieLinzess, Synthroid$64$26,52077 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,843 family providers in Maryland.

Other family in Oakland

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →